巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    BioMarin Pharmaceutical

    BMRN
    79.700
    0.420
    0.53%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・BioMarin Pharmaceutical - 延遲價格・最後更新於 20/05 12:15
    最高位
    80.670
    最低位
    78.260
    開市價
    --
    前收市價
    79.280
    成交量(千)
    63.84
    成交額(百萬)
    42.42
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    14,744.13
    市盈率
    419.470
    息率
    --
    差價
    --
    52週高低
    94.200 - 71.590
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    BioMarin Pharmaceutical
    證券代碼
    BMRN.US
    所屬板塊
    Biotechnology
    公司業務
    BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) is poised to potentially launch in the 2022-23 timeframe.
    發行量
    184032162
    公司總部
    770 Lindaro Street
    公司網址
    http://www.bmrn.com
    公司電郵
    ir@bmrn.com
    公司電話
    +1 415 506-6700
    暫無內容

    關於

    BioMarin Pharmaceutical(BMRN.US)所屬的行業板塊為Biotechnology。
    BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) is poised to potentially launch in the 2022-23 timeframe.
    詳細公司背景可參考: http://www.bmrn.com